10-K: Raphael Pharmaceutical Inc. Extends Board Member Appointment and Reports on Pre-Clinical Progress in Annual Filing

Raphael Pharmaceutical Inc. extends a board member's appointment and provides an update on its pre-clinical development of cannabinoid-based therapies for rheumatoid arthritis and COVID-19 related inflammation in its annual report.

Summary

• Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, is focused on developing cannabinoid-based therapies.
• The company's lead product candidate is for the treatment of rheumatoid arthritis (RA), and they are also developing a treatment for hyperinflammatory syndrome related to COVID-19.
• Pre-clinical studies have been completed at Rambam Health Care Campus, showing promising anti-inflammatory effects of their formulas on immune cells and in mouse models.
• A proposal for a clinical trial of a cannabis-based drug for COVID-19 was accepted by the Ministry of Health of Israel (MOH) in March 2023.
• The company plans to submit a human trial application for their RA product in the second quarter of 2024.
• Raphael is developing a patentable formula combining purified cannabinoids to treat rheumatoid diseases, based on studies of cannabinoid receptors and immune regulation.
• The company relies on third parties for manufacturing and commercialization, intending to license their formulas to GMP-approved manufacturers and distributors.
• As of December 31, 2023, the company had approximately $0.23 million in cash and cash equivalents and a working capital of $0.26 million.
• The company reported a net loss of approximately $1.28 million for the year ended December 31, 2023, compared to $3.36 million in 2022.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive progress in pre-clinical development and regulatory approvals, the company's financial situation is concerning, with significant losses and a going concern warning. The reliance on third parties and the competitive landscape also add to the uncertainty.

Positives

• Pre-clinical studies have shown promising anti-inflammatory effects of the company's formulas.
• The MOH has accepted the company's proposal for a clinical trial of a cannabis-based drug for COVID-19.
• The company is developing a patentable formula combining purified cannabinoids for rheumatoid diseases.
• The company has a research agreement with Rambam MT, with joint ownership of any IP created.
• The company intends to license its formulas to GMP-approved manufacturers and distributors.

Negatives

• The company has incurred significant operating losses since its inception and anticipates continued losses.
• The company has not generated revenue from any product candidate and may never be profitable.
• The company expects to need substantial additional funding to complete the development of its product candidates.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is heavily dependent on the success of its product candidates, which are in pre-clinical development.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company holds no patents on its products and relies on proprietary technology that may be difficult to protect.
• The company relies on third parties for manufacturing and may face supply issues.

Risks

• The company has a limited operating history and has incurred significant operating losses.
• The company has not generated revenue from any product candidate and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available.
• The company is heavily dependent on the success of its product candidates, which are in pre-clinical development.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company holds no patents on its products and relies on proprietary technology that may be difficult to protect.
• The company relies on third parties for manufacturing and may face supply issues.
• The company's executive officers and certain stockholders possess the majority of the voting power.
• The company's headquarters and significant operations are located in Israel, which is subject to political and military instability.
• The company's common stock has limited liquidity and may be difficult to resell.

Future Outlook

The company plans to continue research and development of its RA and COVID-19 product candidates, seek regulatory approvals, and commercialize its products through licensing agreements. They anticipate needing additional funding to support these activities.

Management Comments

• The company intends to leverage the knowledge of its team in order to complete the clinical trials needed to receive approvals of our product candidates from applicable regulatory authorities.
• The company's vision is to emerge as a pioneering company at the forefront of formulating pharmaceutical drugs that harness the potential of purified cannabinoids and full-spectrum CBD oil.
• The company's primary mission is to cater to the unmet medical requirements of patients grappling with various disorders, with a particular focus on conditions linked to inflammation, such as chronic lung inflammation, RA and COVID-19.

Industry Context

The document highlights the growing interest in cannabinoid-based therapies within the pharmaceutical industry, particularly for inflammatory conditions. The company's focus on RA and COVID-19 related inflammation aligns with current medical needs and research trends. The document also acknowledges the competitive landscape and the need for timely development to stay ahead of competitors.

Comparison to Industry Standards

• The document mentions several existing treatments for RA, including Sarilumab, Abatacept, Adalimumab, and others, with annual costs ranging from $15,000 to over $20,000 per patient.
• The company believes its RA product candidate, if approved, will be available at a lower price than existing treatments.
• The document notes that some RA patients do not respond well to existing treatments, highlighting the need for new therapies.
• The company's approach of using cannabinoids aligns with a growing trend in pharmaceutical research, but it also faces competition from companies developing both cannabis-based and traditional therapies.
• The document references a multicenter randomized control trial on medical cannabidiol in Danish patients with RA and Ankylosing Spondylitis, indicating that other companies are also exploring this area.

Related Party Transactions

• The company has entered into consulting agreements with its executive officers, who are also members of the board of directors.
• The company has issued shares and warrants to related parties as compensation for services.
• The company has a research agreement with Rambam MT, with joint ownership of any IP created.
• The company has an agreement with Way of Life Cannabis Ltd. for the supply of CBD oil, which includes the issuance of shares and a royalty fee.

Stakeholder Impact

• Shareholders face the risk of potential losses due to the company's financial situation and the uncertainty of product development.
• Employees and consultants are subject to the company's ability to secure funding and continue operations.
• Patients may benefit from the development of new therapies for RA and COVID-19 related inflammation, but the timeline for availability is uncertain.
• Third-party manufacturers and distributors may have opportunities to partner with the company if its products receive regulatory approval.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company plans to submit a human trial application for its RA product in the second quarter of 2024.
• The company will continue to develop its patentable formula combining purified cannabinoids for rheumatoid diseases.
• The company will continue to seek regulatory approvals for its product candidates.
• The company will seek to enter into royalty agreements with GMP-approved manufacturers and distributors.

Key Dates

Keywords

cannabinoids, rheumatoid arthritis, COVID-19, clinical trials, pharmaceutical, CBD, inflammation, pre-clinical, drug development, regulatory approval